Bricoma 0.2% Eye Drops

Bricoma 0.2% Eye Drops সম্পর্কে

বাংলাদেশে Bricoma 0.2% Eye Drops আই ড্রপ হিসেবে পাওয়া যায়; এতে Brimonidine Tartrate আছে (.২ %)। Bricoma 0.2%-এর সাথে Brimonidine Tartrate-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। Bricoma 0.2% প্রস্তুত করেছে Opsonin Pharma Limited। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।

Brimonidine Tartrate-এর ৩টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত।

Bricoma 0.2% Eye Drops কী?

Bricoma 0.2% comes as a eye drops with.2 % of Brimonidine Tartrate, from Opsonin Pharma Limited. Bricoma 0.2% eye drops are a prescription eye medicine with the active ingredient Brimonidine Tartrate at a strength of.2 %. It belongs to a group of drugs used for glaucoma and related eye pressure problems. Whether it suits you is a decision for your doctor.

Bricoma 0.2%-এর ব্যবহার

It is a medicine for eye pressure control and is not for treating other eye infections or general pain. Do not use it for any other purpose without medical advice. Bricoma 0.2% eye drops are used to lower raised pressure inside the eye in adults with open-angle glaucoma or ocular hypertension. Your doctor will decide if it is suitable for you.

Bricoma 0.2% কীভাবে ব্যবহার করবেন

Wash your hands before use and avoid letting the dropper tip touch your eye, eyelid or any surface. Use Bricoma 0.2% only as directed by your doctor. Swallow the eye drops whole with water. If you miss a dose, ask your doctor or pharmacist what to do. The doctor decides the dose and course for you.

Bricoma 0.2%-এর পার্শ্বপ্রতিক্রিয়া

Call your doctor if side effects are severe, do not settle, or if you notice any eye or vision problem. Some people may notice dry mouth, redness, burning or stinging, headache, blurred vision, a feeling of something in the eye, tiredness or drowsiness, or itchy eyes. Tell your doctor if any side effect bothers you or does not go away. Ask your pharmacist about anything that worries you.

সতর্কতা ও নিরাপত্তা

It is not for people allergic to Brimonidine Tartrate or those taking MAO inhibitor medicines. Pregnancy and breastfeeding need medical advice, as there is limited information on use in these situations. Tell your doctor before using Bricoma 0.2% if you have severe heart disease, depression, poor circulation, low blood pressure on standing, or other serious health problems.

সাধারণ প্রশ্ন

Why is Bricoma 0.2% prescribed?

It is a medicine for eye pressure control and is not for treating other eye infections or general pain. Do not use it for any other purpose without medical advice.

How should I take Bricoma 0.2%?

Wash your hands before use and avoid letting the dropper tip touch your eye, eyelid or any surface. Use Bricoma 0.2% only as directed by your doctor.

What should I watch for while using Bricoma 0.2%?

Call your doctor if side effects are severe, do not settle, or if you notice any eye or vision problem. Some people may notice dry mouth, redness, burning or stinging, headache, blurred vision, a feeling of something in the eye, tiredness or drowsiness, or itchy eyes.

Is Bricoma 0.2% safe for everyone?

It is not for people allergic to Brimonidine Tartrate or those taking MAO inhibitor medicines. Pregnancy and breastfeeding need medical advice, as there is limited information on use in these situations.

নির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Brimonidine Tartrate 0.2% ophthalmic solution is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Brimonidine Tartrate 0.15% ophthalmic solution is indicated for the control of intraocular pressure in patients with chronic open-angle ... Read moreBrimonidine Tartrate 0.2% ophthalmic solution is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Brimonidine Tartrate 0.15% ophthalmic solution is indicated for the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

Brimonidine Tartrate 0.025% ophthalmic solution relieves redness of the eye due to minor eye irritations.

ফার্মাকোলজি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Brimonidine is an α-2 adrenoreceptor agonist that is more selective for the α-2 adrenoreceptor than α-1. Topical administration of Brimonidine Tartrate eye drops decreases intraocular pressure (IOP) in humans. When used as directed Brimonidine Tartrate have the action of reducing elevated IOP with minimal effect on cardiovascular parametres. Brimonidine Tartrate eye drops have a rapid onset of action with the peak ocular hypotensive effect occurring at two hours post-dosing. The duration of effect is 12 hours or greater. Fluorophotometric studies in animals and humans suggest that Brimonidine Tartrate has a dual mechanism of action. Brimonidine Tartrate eye drops lower IOP by reducing aqueous humor production and enhancing uveoscleral outflow.

মাত্রা ও সেবনবিধি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

0.2% ophthalmic solution: The recommended dose is one drop of 0.2% ophthalmic solution in the affected eye(s) three times daily, approximately 8 hours apart. This ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.

0.15% ophthalmic solution: The recommended dose is one drop of 0.15% ophthalmic solution in the affected eye(s) three times daily, approximately 8 hours apart.

0.025% ophthalmic solution: Instill 1 drop in the affected eye(s) every 6-8 hours. Do not use it more than 4 times daily. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.

ঔষধের মিথষ্ক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Although specific drug interaction studies have not been conducted with Brimonidine Tartrate ophthalmic solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. Alpha-agonists, as a class, may reduce pulse and blood pressure. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), antihypertensives and/or cardiac glycosides is advised. Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with Brimonidine Tartrate ophthalmic solution in humans can lead to resulting interference with the IOP lowering effect. No data on the level of circulating catecholamines after administration of Brimonidine Tartrate ophthalmic solution are available. Caution, however, is advised in patients taking Tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.

প্রতিনির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Brimonidine Tartrate ophthalmic solution is contraindicated in patients with hypersensitivity to Brimonidine Tartrate. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.

পার্শ্ব প্রতিক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus. Events occurring in approximately 3-9% of the subjects, in descending order included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain. The following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope.

গর্ভাবস্থায় ও স্তন্যদানকালে

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

There are no adequate and well-controlled studies in pregnant women. In animal studies, Brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Brimonidine Tartrate ophthalmic solution 0.2% should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk; in animal studies Brimonidine Tartrate was excreted in breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

সতর্কতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Although Brimonidine Tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. Brimonidine Tartrate ophthalmic solution should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans.

সংরক্ষণ

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Store below 30°C in a cool and dry place protected from light. Keep out of reach of children. Do not touch the dropper tip to surfaces since this may contaminate the solution. Do not use after 30 days of first opening.

বিকল্প ব্র্যান্ড: Brimonidine Tartrate

একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।

ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।